Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
Total Valuation
BioMarin Pharmaceutical has a market cap or net worth of $10.29B. The enterprise value is $9.53B.
Market Cap$10.29B
Enterprise Value$9.53B
Share Statistics
BioMarin Pharmaceutical has 192,114,350 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding192,114,350
Owned by Insiders0.45%
Owned by Institutions0.23%
Financial Efficiency
BioMarin Pharmaceutical’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 5.97%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)5.97%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee938.79K
Profits Per Employee140.41K
Employee Count3,040
Asset Turnover0.41
Inventory Turnover0.47
Valuation Ratios
The current PE Ratio of BioMarin Pharmaceutical is 20.1. BioMarin Pharmaceutical’s PEG ratio is 0.19.
PE Ratio20.1
PS Ratio4.38
PB Ratio2.21
Price to Fair Value2.21
Price to FCF26.27
Price to Operating Cash Flow10.93
PEG Ratio0.19
Income Statement
In the last 12 months, BioMarin Pharmaceutical had revenue of 2.85B and earned 426.86M in profits. Earnings per share was 2.25.
Revenue2.85B
Gross Profit2.27B
Operating Income484.21M
Pretax Income541.76M
Net Income426.86M
EBITDA650.53M
Earnings Per Share (EPS)2.25
Cash Flow
In the last 12 months, operating cash flow was 913.98M and capital expenditures -82.61M, giving a free cash flow of 831.36M billion.
Operating Cash Flow913.98M
Free Cash Flow831.36M
Free Cash Flow per Share4.33
Dividends & Yields
BioMarin Pharmaceutical pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.45
52-Week Price Change-18.85%
50-Day Moving Average54.78
200-Day Moving Average59.93
Relative Strength Index (RSI)49.27
Average Volume (3m)2.52M
Important Dates
BioMarin Pharmaceutical upcoming earnings date is Feb 25, 2026, After Close (Confirmed).
Last Earnings DateOct 27, 2025
Next Earnings DateFeb 25, 2026
Ex-Dividend Date―
Financial Position
BioMarin Pharmaceutical as a current ratio of 5.33, with Debt / Equity ratio of 9.85%
Current Ratio5.33
Quick Ratio3.29
Debt to Market Cap0.05
Net Debt to EBITDA-0.47
Interest Coverage Ratio38.23
Taxes
In the past 12 months, BioMarin Pharmaceutical has paid 114.90M in taxes.
Income Tax114.90M
Effective Tax Rate0.21
Enterprise Valuation
BioMarin Pharmaceutical EV to EBITDA ratio is 18.72, with an EV/FCF ratio of 25.62.
EV to Sales4.27
EV to EBITDA18.72
EV to Free Cash Flow25.62
EV to Operating Cash Flow21.27
Balance Sheet
BioMarin Pharmaceutical has $1.48B in cash and marketable securities with $596.66M in debt, giving a net cash position of $881.18M billion.
Cash & Marketable Securities$1.48B
Total Debt$596.66M
Net Cash$881.18M
Net Cash Per Share$4.59
Tangible Book Value Per Share$27.40
Margins
Gross margin is 81.32%, with operating margin of 16.97%, and net profit margin of 14.96%.
Gross Margin81.32%
Operating Margin16.97%
Pretax Margin18.98%
Net Profit Margin14.96%
EBITDA Margin22.81%
EBIT Margin19.42%
Analyst Forecast
The average price target for BioMarin Pharmaceutical is $91.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$91.20
Price Target Upside70.24% Upside
Analyst ConsensusStrong Buy
Analyst Count22
Revenue Growth Forecast12.31%
EPS Growth Forecast60.21%